Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 2/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.35 |
| ▸ | PPARG | P37231 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | PTAFR | P25105 | 1/20 | 0.33 |
| ▸ | VNN1 | O95497 | 1/20 | 0.33 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26565167 | 0.93 | LTB4R (0.39) | LTB4RMTNR1BMTNR1ANR1H2NR1H3 | |
| SCHEMBL26565315 | 0.88 | LTB4R (0.36) | LTB4RMTNR1BMTNR1APPARG | |
| SCHEMBL26565186 | 0.85 | LTB4R (0.38) | LTB4RMTNR1BMTNR1APPARGAKR1C3 | |
| SCHEMBL26565239 | 0.85 | LTB4R (0.38) | LTB4RMTNR1BMTNR1ANR1H2NR1H3 | |
| SCHEMBL26565302 | 0.84 | PKM (0.35) | LTB4RMTNR1BMTNR1APPARGAVPR1B | |
| SCHEMBL26565274 | 0.82 | LTB4R (0.37) | LTB4RMTNR1BMTNR1ANR1H2NR1H3 | |
| SCHEMBL26564916 | 0.79 | CNR2 (0.39) | LTB4RVNN1AVPR1B | |
| SCHEMBL25652995 | 0.78 | CYP4F2 (0.42) | LTB4R | |
| SCHEMBL26565169 | 0.77 | LTB4R (0.35) | LTB4RAVPR1BAKR1C3AKR1C2 | |
| SCHEMBL25224251 | 0.76 | L3MBTL1 (0.43) | LTB4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018011-B2 | Macrocyclic compounds and compositions, and methods of preparing and using the same | KURA ONCOLOGY, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230322711-A1 | MACROCYCLIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF PREPARING AND USING THE SAME | WUXI APPTEC (HONG KONG) LIMITED (CN) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018011-B2 | Macrocyclic compounds and compositions, and methods of preparing and using the same | FNTA, FDPS, GGPS1 | LTB4R 2287/4885MTNR1B 4567/4885MTNR1A 4658/4885 |
| US-20230322711-A1 | MACROCYCLIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF PREPARING AND USING THE SAME | FNTA, FDPS, GGPS1 | LTB4R 2287/4885MTNR1B 4567/4885MTNR1A 4658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.